الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - krabbamein, squamous cell - Æxlishemjandi lyf - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - Æxlishemjandi lyf - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

eckert ziegler radiopharma gmbh - yttrium (90y) chloride - radionuclide imaging - greining geislavirkja - aðeins má nota við geislamerktu flutningsameindir, sem hafa verið sérstaklega þróaðir og leyfð til geislamerktar með þessu radíónúklíði. radiopharmaceutical undanfari - ekki ætlað fyrir bein að nota í sjúklingar.

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - betamethasonum díprópíónat; calcipotriolum inn - smyrsli - 50 míkrog/g + 0,5 mg/g

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

hra pharma rare diseases - mitotane - nýrnahettubólga - Æxlishemjandi lyf - einkenni meðferðar á háþróaðri (ómeðhöndluð, meinvörpum eða endurteknum) barkabólgu í nýrnahettum. Áhrif lysodren á virka ekki að mynda óeðlilega bylgja krabbamein er ekki stofnað.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

life molecular imaging gmbh - florbetaben (18f) - radionuclide imaging; alzheimer disease - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. neuraceq er radiopharmaceutical fram í sneiðmyndatöku losun höfði (gÆludÝr) hugsanlegur beta amyloid neuritic sýklum þéttleika í heila fullorðinn sjúklinga með vitsmunalegum skert sem eru metin fyrir alzheimer (ad) og aðrar ástæður vitsmunalegum skert. neuraceq ætti að vera notuð í tengslum við mat klínískum. neikvæð skanna sýnir dreifður eða enginn skellum, sem er ekki í samræmi við greiningu á ad.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - Ónæmisbælandi lyf - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - pamidronat dínatríum - innrennslisþykkni, lausn - 9 mg/ml

أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - pamidronat dínatríum - innrennslisþykkni, lausn - 6 mg/ml